所有图片(1)
About This Item
经验公式（希尔记法）:
C24H26N2O4
CAS号:
分子量:
406.47
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
carvedilol
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC
InChI
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChI key
OGHNVEJMJSYVRP-UHFFFAOYSA-N
基因信息
human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Carvedilol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity.
Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Aquatic Chronic 2 - STOT RE 2
靶器官
Liver,spleen,Uterus (including cervix),Adrenal gland
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Péter Ferdinandy et al.
Pharmacological reviews, 66(4), 1142-1174 (2014-09-28)
Pre-, post-, and remote conditioning of the myocardium are well described adaptive responses that markedly enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and provide therapeutic paradigms for cardioprotection. Nevertheless, more than 25 years after the
George L Bakris et al.
Reviews in cardiovascular medicine, 9(2), 96-105 (2008-07-29)
Few patients with hypertension meet recommended target blood pressure goals, and most hypertensive patients require at least 2 antihypertensive medications from different pharmacologic classes to adequately lower blood pressure. beta-Blockers are guideline-recommended for the treatment of hypertension with compelling indications.
James J DiNicolantonio et al.
The American journal of cardiology, 113(3), 565-569 (2013-12-18)
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica
Gonçalo C Pereira et al.
Current pharmaceutical design, 17(20), 2113-2129 (2011-07-02)
Mitochondria have long been involved in several cellular processes beyond its role in energy production. The importance of this organelle for cardiac tissue homeostasis has been greatly investigated and its impairment can lead to cell death and consequent organ failure.
Carol Chen-Scarabelli et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 12(6), 391-401 (2012-10-16)
β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门